Previously, Angelini et al [44] showed that lapatinib could not revert the HER2-induced senescence phenotype in a constitutive active HER2 (+) (MCF7 Tet-Off/p95HER2) cells, whereas McDermott et al [45] showed lapatinib induced senescent-like phenotype in HER2 positive HCC1419 breast cancer cells. The gene discussed is ERBB2; the disease is breast cancer.